Consensus EPS · Q2 2026
$1.34
Consensus revenue · Q2 2026
$2.3B
Analysts
13
Expected report
Jul 28, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 13 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $2.3B | $2.3B | $2.4B |
| EPS | $1.32 | $1.34 | $1.36 |
| EBITDA | $608.2M | $616.1M | $624.1M |
| EBIT | $403.9M | $409.1M | $414.4M |
| Net income | $323M | $325.4M | $330.3M |
- Revenue$2.3B
- EPS$1.34
- EBITDA$616.1M
- EBIT$409.1M
- Net income$325.4M
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $2.1B | $2.1B | +0.7% | $1.12 | $1.08 | +3.2% |
- Q1 2026+0.7%+3.2%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Xylem (XYL) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 2 analysts.
- Low
- $133.00
- Consensus
- $150.89
- Median
- $157.00
- High
- $161.00
- Current
- $119.75
- Upside
- +26.0%
Upside calculated vs most recent trading price of $119.75.
Analyst ratings
Consensus: Hold — based on 40 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 20, 2026 | Stifel | maintain | Buy | Buy |
| Jul 16, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jun 25, 2026 | Jefferies | upgrade | Hold | Buy |
| Apr 29, 2026 | UBS | maintain | Neutral | Neutral |
| Apr 29, 2026 | Stifel | maintain | Buy | Buy |
| Apr 29, 2026 | Oppenheimer | maintain | Outperform | Outperform |
| Apr 29, 2026 | Citigroup | maintain | Buy | Buy |
| Apr 29, 2026 | Barclays | maintain | Overweight | Overweight |
| Apr 21, 2026 | UBS | downgrade | Buy | Neutral |
| Apr 16, 2026 | JP Morgan | maintain | Overweight | Overweight |
- Jul 20, 2026StifelBuy
- Jul 16, 2026RBC CapitalOutperform
- Jun 25, 2026JefferiesBuy
- Apr 29, 2026UBSNeutral
- Apr 29, 2026StifelBuy
- Apr 29, 2026OppenheimerOutperform
- Apr 29, 2026CitigroupBuy
- Apr 29, 2026BarclaysOverweight
- Apr 21, 2026UBSNeutral
- Apr 16, 2026JP MorganOverweight
Frequently asked questions
Xylem (XYL) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.